We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
African Med | LSE:AMEI | London | Ordinary Share | IM00B39HQT38 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.225 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Impairment reviews of non-current assets are carried out on each cash-generating unit identified in accordance with IAS 36 "Impairment of Assets". At each reporting date, where there are indicators of impairment, the net book value of the cash generating unit is compared with the associated fair value. In prior periods investigation into alleged financial and administrative irregularities has identified potential overpayments to certain suppliers for plant and equipment. Independent experts and forensic auditors were engaged to ascertain the likely extent of any overpayment. In instances where financial irregularities were quantified, the financial impact was taken to the income statement as Loss from financial irregularities. Where indicators of overpayment exist, an impairment provision was raised on an assessment assisted by independent experts of the extent of the overpayment, based on market values of fit for purpose equipment purchased. Due to the nature of the alleged financial irregularities, the precise overpayments cannot be determined, however the directors believe the provision is materially adequate based on the information currently available. In the prior year assets reviewed for impairment totalled $9,140,127 in the current year these assets were considered to be at the correct value after impairment.
Valuation of cash generating units
The Group tests annually whether property, plant and equipment has suffered any impairment. Determining whether the assets are impaired requires an estimation of the value in use of the cash-generating unit (CGU). The value in use calculation requires estimated future cash flows expected to arise from the CGU to be discounted at a suitable discount rate in order to calculate the present value. Actual outcomes could vary significantly from these estimates. Please refer to note 6 for further information.
The key assumptions for the discounted cashflow valuation calculations are those relating to discount rates, growth rates and cashflow forecasts derived from the most recent financial budgets and forecasts approved by management covering a five year period. Cash flows beyond the five year period are extrapolated using an estimated growth rate which is based on the average long term growth rate for the country. The pre-tax discount rates are based on the Group's weighted average cost of capital. The rates used to discount the forecast cash flows are between 13% and 21%, reflecting each operations specific risk level.
Convertible loan note valuation
Calculation of the equity element contained within the convertible loan note valuation contained an estimate from the board on a market related interest rate for a standard unsecured loan of $5.7 m at the balance sheet date. This was deemed to be 15% per annum.
5. Loss from financial irregularities
Prior year investigations into the alleged financial irregularities which occurred during the tenure of Dr. Solanki, the former CEO of the Company, resulted in criminal charges being laid against the former manager of the Harare Trauma Centre. Arrest warrants were issued in respect of Dr. Solanki and his appointed manager in South Africa by the South African Police Service.
The board remains committed to further civil action in an attempt to seek compensation for the losses suffered, not only in relation to the fraud and/or theft but also in relation to losses suffered in connection with the acquisition of VIP Healthcare Solutions Limited by the Company, in all jurisdictions.
Other than in respect of on-going investigation costs the Company is confident that all other financial losses resulting from the matters referred to above have now been reflected in the Group's income statement.
6. Asset Impairment
Current year losses have led to the review of the value of assets contained within the various cash generating units contained in the group. Details of any impairments arising from the aforesaid review are detailed in the note below.
In February 2012 our hospital in Harare, Zimbabwe was illegally and forcibly occupied by previous members of our management team led by Dr Vivek Solanki. This has resulted in large scale losses of revenue from this point onwards and an impairment review of the hospital assets was carried out, details of which are in the note below. The group has been awarded a date to appeal the illegal occupation in mid-September 2012.
Prior year investigations into alleged financial and administrative irregularities identified potential overpayments to certain suppliers for plant and equipment in the period 1 March 2010 to 28 February 2011. Independent experts and forensic auditors were engaged to ascertain the likely extent of overpayment. Where indicators of overpayment existed, impairment provisions were raised based on an assessment by independent experts of the extent of overpayment, based on market values of fit for purpose equipment. Impairments arising from potential overpayment were recognised notwithstanding that the recoverable amount based on value in use may have been in excess of amounts actually paid.
The review of carrying amounts of property, plant and equipment and intangible assets at 29 February 2012 indicated actual impairment write downs on the following assets:
Impairment Impairment write down write down Basis of recoverable Valuation 29 February 28 February amount undertaken 2012 2011 by Asset or Asset Class $'000 $'000 CGU Note ---------------- ------------------ --------------------------- ----------------- ------------------ ------------------ ---------- Harare Land and Discounted cash Internal 1,779 - (a) buildings flow valuation assessment Harare Medical Discounted cash Internal 1,001 - (a) equipment flow valuation assessment Harare Motor Discounted cash Internal 65 - (a) vehicles flow valuation assessment Harare Other assets Discounted cash Internal 564 - (a) flow valuation assessment Harare Assets under Discounted cash Internal 215 - (a) construction flow valuation assessment Maputo Medical Fair value Internal 414 - (b) equipment assessment Maputo Motor Fair value Internal 4 - (b) vehicles assessment Maputo Other assets Fair value Internal 97 - (b) assessment Dar es Medical Fair value Internal 162 - (c) Salaam equipment assessment Aviation Aircraft Fair value Arm's length 1,057 - (d) sale Loan Loans and Internal receivable receivables Fair value assessment (131) 2,481 (e) Maputo Land and Fair value Independent - 18 (f) buildings expert Maputo Medical Fair value Independent - 129 (f) equipment expert Maputo Other assets Fair value Independent - 12 (f) expert Harare Assets under Fair value Independent - (1,704) (g) construction expert Dar es Medical Discounted cash Internal - 653 (h) Salaam equipment flow valuation assessment Dar es Other assets Discounted cash Internal - 218 (h) Salaam flow valuation assessment
1 Year African Med Chart |
1 Month African Med Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions